Rapid communication Open Access
Like 0


Europe has experienced a large COVID-19 wave caused by the Delta variant in winter 2021/22. Using mathematical models applied to Metropolitan France, we find that boosters administered to ≥ 65, ≥ 50 or ≥ 18 year-olds may reduce the hospitalisation peak by 25%, 36% and 43% respectively, with a delay of 5 months between second and third dose. A 10% reduction in transmission rates might further reduce it by 41%, indicating that even small increases in protective behaviours may be critical to mitigate the wave.


Article metrics loading...

Loading full text...

Full text loading...



  1. Bosetti P, Tran Kiem C, Andronico A, Colizza V, Yazdanpanah Y, Fontanet A, et al. Epidemiology and control of SARS-CoV-2 epidemics in partially vaccinated populations: a modeling study applied to France. Paris: Institut Pasteur; 2021. Available from: https://hal-pasteur.archives-ouvertes.fr/pasteur-03272638v2
  2. Béraud G, Kazmercziak S, Beutels P, Levy-Bruhl D, Lenne X, Mielcarek N, et al. The French connection: the first large population-based contact survey in France relevant for the spread of infectious diseases. PLoS One. 2015;10(7):e0133203.  https://doi.org/10.1371/journal.pone.0133203  PMID: 26176549 
  3. Viner RM, Mytton OT, Bonell C, Melendez-Torres GJ, Ward J, Hudson L, et al. Susceptibility to SARS-CoV-2 infection among children and adolescents compared with adults: a systematic review and meta-analysis. JAMA Pediatr. 2021;175(2):143-56.  https://doi.org/10.1001/jamapediatrics.2020.4573  PMID: 32975552 
  4. Davies NG, Klepac P, Liu Y, Prem K, Jit M, Eggo RM, CMMID COVID-19 working group. Age-dependent effects in the transmission and control of COVID-19 epidemics. Nat Med. 2020;26(8):1205-11.  https://doi.org/10.1038/s41591-020-0962-9  PMID: 32546824 
  5. Tartof SY, Slezak JM, Fischer H, Hong V, Ackerson BK, Ranasinghe ON, et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. Lancet. 2021;398(10309):1407-16.  https://doi.org/10.1016/S0140-6736(21)02183-8  PMID: 34619098 
  6. Collin A, Hejblum BP, Vignals C, Lehot L, Thiébaut R, Moireau R, et al. Using population based Kalman estimator to model COVID-19 epidemic in France: estimating the effects of non-pharmaceutical interventions on the dynamics of epidemic. medRxiv. 2021.07.09.21260259. preprint.  https://doi.org/10.1101/2021.07.09.21260259  https://doi.org/10.1101/2021.07.09.21260259 
  7. Twohig KA, Nyberg T, Zaidi A, Thelwall S, Sinnathamby MA, Aliabadi S, et al. , COVID-19 Genomics UK (COG-UK) consortium. Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study. Lancet Infect Dis. 2022;22(1):35-42.  https://doi.org/10.1016/S1473-3099(21)00475-8  PMID: 34461056 
  8. Bager P, Wohlfahrt J, Fonager J, Rasmussen M, Albertsen M, Michaelsen TY, et al. , Danish Covid-19 Genome Consortium. Risk of hospitalisation associated with infection with SARS-CoV-2 lineage B.1.1.7 in Denmark: an observational cohort study. Lancet Infect Dis. 2021;21(11):1507-17.  https://doi.org/10.1016/S1473-3099(21)00290-5  PMID: 34171231 
  9. Bar-On YM, Goldberg Y, Mandel M, Bodenheimer O, Freedman L, Kalkstein N, et al. Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel. N Engl J Med. 2021;385(15):1393-400.  https://doi.org/10.1056/NEJMoa2114255  PMID: 34525275 
  10. Tran Kiem C, Bosetti P, Paireau J, Crépey P, Salje H, Lefrancq N, et al. SARS-CoV-2 transmission across age groups in France and implications for control. Nat Commun. 2021;12(1):6895.  https://doi.org/10.1038/s41467-021-27163-1  PMID: 34824245 
  11. Pulliam JRC, van Schalkwyk C, Govender N, von Gottberg A, Cohen C, Groome MJ, et al. Increased risk of SARS-CoV-2 reinfection associated with emergence of the Omicron variant in South Africa. bioRxiv. 2021.11.11.21266068. preprint.  https://doi.org/10.1101/2021.11.11.21266068  https://doi.org/10.1101/2021.11.11.21266068 

Data & Media loading...

Supplementary data

Submit comment
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error